Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inozyme receives Orphan Drug Designation for INZ-701 from EMA » 07:32
07/21/21
07/21
07:32
07/21/21
07:32
INZY

Inozyme

$18.49 /

+0.21 (+1.15%)

Inozyme Pharma announced…

Inozyme Pharma announced that the European Medicines Agency, or EMA, has granted Orphan Drug Designation to INZ-701 for the treatment of ABCC6 Deficiency. INZ-701, an investigational enzyme replacement therapy, was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the EMA for the treatment of ENPP1 Deficiency. "Obtaining Orphan Drug Designation from the EMA for the treatment of ABCC6 Deficiency marks another important step toward providing relief for patients who currently have no treatment options and positions INZ-701 to become the first-ever available therapy for this condition," said Axel Bolte, MSc, MA, co-founder, president, and chief executive officer of Inozyme.

ShowHide Related Items >><<
INZY Inozyme
$18.49 /

+0.21 (+1.15%)

INZY Inozyme
$18.49 /

+0.21 (+1.15%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$18.49 /

+0.21 (+1.15%)

  • 24
    Jul
Hot Stocks
Inozyme appoints Gayle Gironda as SVP, human resources » 07:37
07/13/21
07/13
07:37
07/13/21
07:37
INZY

Inozyme

$17.56 /

+0.25 (+1.44%)

, BMY

Bristol-Myers

$67.50 /

+0.35 (+0.52%)

Inozyme Pharma (INZY)…

Inozyme Pharma (INZY) announced that Gayle Gironda has been appointed as senior vice president of human resources. Most recently, Ms. Gironda served as vice president, human resources, global hematology and global market access at Bristol Myers Squibb (BMY).

ShowHide Related Items >><<
INZY Inozyme
$17.56 /

+0.25 (+1.44%)

BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

INZY Inozyme
$17.56 /

+0.25 (+1.44%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/29/21 Mizuho
Bristol-Myers likely to settle CVR litigation, says Mizuho
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
06/25/21 BTIG
Prothena price target raised to $65 from $29 at BTIG
INZY Inozyme
$17.56 /

+0.25 (+1.44%)

BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

  • 24
    Jul
BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

BMY Bristol-Myers
$67.50 /

+0.35 (+0.52%)

Over a month ago
Conference/Events
Inozyme management to meet virtually with Wedbush » 04:55
06/14/21
06/14
04:55
06/14/21
04:55
INZY

Inozyme

$16.64 /

-1.61 (-8.82%)

Virtual Meeting to be…

Virtual Meeting to be held on June 14 hosted by Wedbush.

ShowHide Related Items >><<
INZY Inozyme
$16.64 /

-1.61 (-8.82%)

INZY Inozyme
$16.64 /

-1.61 (-8.82%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$16.64 /

-1.61 (-8.82%)

  • 24
    Jul
Conference/Events
Inozyme management to meet virtually with Wedbush » 12:56
06/10/21
06/10
12:56
06/10/21
12:56
INZY

Inozyme

$17.90 /

+0.33 (+1.88%)

Virtual Meeting to be…

Virtual Meeting to be held on June 14 hosted by Wedbush.

ShowHide Related Items >><<
INZY Inozyme
$17.90 /

+0.33 (+1.88%)

INZY Inozyme
$17.90 /

+0.33 (+1.88%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$17.90 /

+0.33 (+1.88%)

  • 24
    Jul
Hot Stocks
Inozyme announces acceptance of first european CTA for phase 1/2 of INZ-701 » 07:35
06/09/21
06/09
07:35
06/09/21
07:35
INZY

Inozyme

$17.33 /

-0.67 (-3.72%)

Inozyme Pharma announced…

Inozyme Pharma announced the acceptance of its Clinical Trial Application, or CTA, from the National Agency for the Safety of Medicines and Health Products in France to allow initiation of its Phase 1/2 clinical trial of INZ-701, as a potential treatment for ABCC6 Deficiency. Inozyme plans to initiate its Phase 1/2 trial in mid-2021. This CTA was submitted and accepted as part of ANSM's Fast Track procedure designed to reduce processing times for clinical trial authorization requests for innovative medical products. "The acceptance of this CTA marks another important regulatory milestone for Inozyme and a key advancement for INZ-701 as a potential treatment for people living with ABCC6 Deficiency," said Axel Bolte, MSc, MBA, co-founder, president, and CEO of Inozyme Pharma. "We are well-positioned to execute on our planned clinical study and the notable level of interest from the ABCC6 Deficiency community underscores the urgent need for therapeutic options. I want to express my thanks to the team at Inozyme and our external collaborators, all of whom have been instrumental in our continued progress."

ShowHide Related Items >><<
INZY Inozyme
$17.33 /

-0.67 (-3.72%)

INZY Inozyme
$17.33 /

-0.67 (-3.72%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$17.33 /

-0.67 (-3.72%)

  • 24
    Jul
Earnings
Inozyme reports Q1 EPS (47c), consensus (54c) » 06:03
05/12/21
05/12
06:03
05/12/21
06:03
INZY

Inozyme

$16.12 /

+0.12 (+0.75%)

Cash, cash equivalents,…

Cash, cash equivalents, and investments were $147.6M as of March 31. The company expects that its existing cash, cash equivalents, and investments will be sufficient to enable funding of its operating expenses and capital expenditure requirements into Q4 of 2022. "We closed 2020 with the clearance of our IND for INZ-701 by the FDA and our CTA by the MHRA of the UK, both for ENPP1 Deficiency. Since then, we have continued to execute on our plan to deliver a potential therapeutic option for patients with ENPP1 and ABCC6 Deficiencies," said Axel Bolte, MSc, MBA, co-founder, president, and chief executive officer of Inozyme Pharma. "We recently reported key findings from the Burden of Illness Study in patients with both ENPP1 Deficiency and ABCC6 Deficiency. Notably, we found patients in different age groups are impacted by these deficiencies in distinct ways, illuminating an age-based shift that reflects the progression of these debilitating genetic diseases. We expect site activation in the United States for our Phase 1/2 clinical trial site for ENPP1 Deficiency in June 2021 and enrollment of the first patient shortly thereafter. Subject to receiving regulatory clearance, we also expect to initiate our planned Phase 1/2 clinical trial of INZ-701 for ABCC6 Deficiency in mid-2021. Our current cash position allows us to appropriately resource each of the key functions necessary to execute on our goals, and is expected to enable our operations into 4Q22."

ShowHide Related Items >><<
INZY Inozyme
$16.12 /

+0.12 (+0.75%)

INZY Inozyme
$16.12 /

+0.12 (+0.75%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$16.12 /

+0.12 (+0.75%)

  • 24
    Jul
Hot Stocks
Inozyme presents preclinical data on INZ-701 for treating ABCC6 deficiency » 07:46
05/07/21
05/07
07:46
05/07/21
07:46
INZY

Inozyme

$16.32 /

-1.16 (-6.64%)

Inozyme Pharma presented…

Inozyme Pharma presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress, are the first to show that an enzyme replacement therapy increased plasma pyrophosphate levels and reduced calcification in an animal model of ABCC6 Deficiency. This study was performed in collaboration with Thomas Jefferson University. Subcutaneous administration of INZ-701 was initiated in ABCC6-deficient mice at five to six weeks of age, the time where initiation of ectopic mineralization in this model is observed. INZ-701 led to a dose-dependent increase in plasma PPi levels at both two and eight weeks after initiation of treatment, leading to significantly lower levels of soft tissue mineralization. Histopathologic examination of tissue biopsies from vehicle-treated mice revealed extensive mineralization in the muzzle skin containing vibrissae, a biomarker of the mineralization process in this model. Compared to vehicle-treated mice, a quantitative calcium assay demonstrated that the amount of calcium in muzzle skin biopsies was reduced by 68% and 74% in mice receiving INZ-701 at dose levels of 2 and 10 mg/kg, respectively.

ShowHide Related Items >><<
INZY Inozyme
$16.32 /

-1.16 (-6.64%)

INZY Inozyme
$16.32 /

-1.16 (-6.64%)

05/04/21 Piper Sandler
Inozyme should be bought up to $40 per share, says Piper Sandler
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
INZY Inozyme
$16.32 /

-1.16 (-6.64%)

  • 24
    Jul
Recommendations
Inozyme should be bought up to $40 per share, says Piper Sandler » 04:51
05/04/21
05/04
04:51
05/04/21
04:51
INZY

Inozyme

/

+

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Inozyme with a $40 price target after taking over coverage of the name. The analyst anticipates first-in-human trials of INZ-701 in patients with ENPP1 deficiency and ABCC6 deficiency by mid-2021 and he likes the chances for success in both programs. He's ae buyer of the stock to levels approaching $40.

ShowHide Related Items >><<
INZY Inozyme
/

+

INZY Inozyme
/

+

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
08/18/20 BofA
Inozyme initiated with a Buy at BofA
INZY Inozyme
/

+

  • 24
    Jul
Over a quarter ago
Hot Stocks
Inozyme publishes data on INZ-701 as potential treatment for ENPP1 deficiency » 07:48
04/29/21
04/29
07:48
04/29/21
07:48
INZY

Inozyme

$17.82 /

-1.06 (-5.61%)

Inozyme Pharma announced…

Inozyme Pharma announced the online pre-publication release of preclinical data suggesting the potential of its lead development candidate, INZ-701, as a treatment for ENPP1 Deficiency. As reported in the Journal of Bone and Mineral Research, in an article titled, "INZ-701 prevents ectopic tissue calcification and restores bone architecture and growth in ENPP1 deficient mice", treatment with INZ-701 was associated with increased plasma levels of pyrophosphate, a potent regulator of mineralization, as well as improvements in several other disease markers and decreased mortality in a mouse model of ENPP1 Deficiency. The JBMR publication highlights the following preclinical findings with INZ-701. Increase of PPi; durable increases in PPi levels were observed after subcutaneous administration of a single dose of INZ-701 in ENPP1-deficient mice; and in a dose-response study, animals injected with INZ-701 showed a dose-dependent elevation in plasma ENPP1 activity and an average increase of approximately 2 microM in plasma PPi. Prevention of calcification: repeated dosing of INZ-701 at 0.2 mg/kg tended to reduce tissue calcium levels in the kidney, spleen, lung, and liver; dosing at 1 mg/kg significantly reduced calcification in most of the tissues; amd dosing at 5 mg/kg completely prevented calcification in all tissues. Correction of bone defects: INZ-701 treatment led to a dose-dependent increase in trabecular number, cortical thickness, bone volume, and bone mineral density. Restoration of growth parameters; INZ-701 treatment resulted in a clear dose response in rescuing slow growth in ENPP1-deficient mice during the first four weeks of the study; by the end of the study, mice treated with INZ-701 gained significant weight and reached approximately 15-16 grams in the 0.2 and 1 mg/kg dosing groups, and approximately 18 grams in the 5 mg/kg dosing group, compared to approximately 20 grams in wild-type mice; and ENPP1-deficient mice dosed with vehicle failed to gain weight from roughly four weeks of age to the end of the study. Improvements in other clinical signs; compared to the vehicle-treated group, ENPP1-deficient mice dosed with 0.2 mg/kg of INZ-701 showed less severe clinical signs associated with ENPP1 deficiency from day 27; mice dosed with 1 mg/kg of INZ-701 did not show any signs of morbidity until the eighth week of the study; and no abnormalities were observed in any WT mice or in ENPP1-deficient mice treated with 5 mg/kg of INZ-701.

ShowHide Related Items >><<
INZY Inozyme
$17.82 /

-1.06 (-5.61%)

INZY Inozyme
$17.82 /

-1.06 (-5.61%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
08/18/20 BofA
Inozyme initiated with a Buy at BofA
INZY Inozyme
$17.82 /

-1.06 (-5.61%)

  • 24
    Jul
Hot Stocks
Inozyme presents data for patients with ENPP1, ABCC6 deficiencies » 07:36
04/14/21
04/14
07:36
04/14/21
07:36
INZY

Inozyme

$19.20 /

+0.44 (+2.35%)

Inozyme Pharma presented…

Inozyme Pharma presented data that highlight the burden of disease for patients and families affected by ENPP1 Deficiency and ABCC6 Deficiency, two devastating and potentially deadly genetic diseases. In a poster entitled, "From the Voice of Patients and Caregivers: Burden of Illness in Infantile Onset ABCC6 and ENPP1 Deficiency," Inozyme and GACI Global reported that patients in different age groups are impacted in different ways, an age-based shift that reflects the progression of these rare genetic diseases. The poster was presented virtually beginning on April 14th at the annual meeting of the American College of Medical Genetics and Genomics. The most frequently reported burdens for patients with ENPP1 Deficiency at all time points were: bone and joint pain, cardiac issues, and mobility issues/fatigue. The most frequently reported symptoms for patients with ABCC6 Deficiency were: gastrointestinal issues, growth and development issues, and cardiac issues. The study also assessed the importance of each burden for each cohort using a weighted score approach: in the ABCC6 Deficiency cohort, fear of the unknown was the heaviest burden, followed by cardiac issues and difficulty with the hospital experience; in the infant ENPP1 Deficiency cohort, cardiac issues were the greatest burden, followed by difficulty with the hospital experience and issues related to growth and development; in the pediatric ENPP1 Deficiency cohort, treatments/medications were most burdensome, followed by issues related to hearing loss and stress/anxiety; and the adult ENPP1 Deficiency cohort was most burdened by issues related to bone/joint pain.

ShowHide Related Items >><<
INZY Inozyme
$19.20 /

+0.44 (+2.35%)

INZY Inozyme
$19.20 /

+0.44 (+2.35%)

08/18/20
Fly Intel: Top five analyst initiations
08/18/20 Wedbush
Wedbush bullish on Inozyme, initiates with an Outperform
08/18/20 Wedbush
Inozyme initiated with an Outperform at Wedbush
08/18/20 BofA
Inozyme initiated with a Buy at BofA
INZY Inozyme
$19.20 /

+0.44 (+2.35%)

  • 24
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.